Joseph A Hedrick

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 6

Top Topics

Mesenchymal Stem Cells

Ankylosing Spondylitis

Top Venues

Journal of immunology (Baltimore, Md. : 1950)

This page only lists publications with an associated author ORCID identifier.

Publications

Mark R Rigby, Beverly Hayes, Yinglei Li, Frank Vercruysse, Joseph A Hedrick, Teresa Quattrin
Two-Year Follow-up From the T1GER Study: Continued Off-Therapy Metabolic Improvements in Children and Young Adults With New-Onset T1D Treated With Golimumab and Characterization of Responders. Diabetes care 46 (3) (2023)
Mark R Rigby, Beverly Hayes, Yinglei Li, Frank Vercruysse, Joseph A Hedrick, Teresa Quattrin
Two-Year Follow-up From the T1GER Study: Continued Off-Therapy Metabolic Improvements in Children and Young Adults With New-Onset T1D Treated With Golimumab and Characterization of Responders. Diabetes care 46 (3) (2023)
Mark R Rigby, Beverly Hayes, Yinglei Li, Frank Vercruysse, Joseph A Hedrick, Teresa Quattrin
Two-Year Follow-up From the T1GER Study: Continued Off-Therapy Metabolic Improvements in Children and Young Adults With New-Onset T1D Treated With Golimumab and Characterization of Responders. Diabetes care 46 (3) (2023)
Ambroise Gilles, Lan Hu, Francesca Virdis, Derek B Sant'Angelo, Nevenka Dimitrova, Joseph A Hedrick, Lisa K Denzin
The MHC Class II Antigen-Processing and Presentation Pathway Is Dysregulated in Type 1 Diabetes. Journal of immunology (Baltimore, Md. : 1950) (2023)
Mark R Rigby, Beverly Hayes, Yinglei Li, Frank Vercruysse, Joseph A Hedrick, Teresa Quattrin
Two-Year Follow-up From the T1GER Study: Continued Off-Therapy Metabolic Improvements in Children and Young Adults With New-Onset T1D Treated With Golimumab and Characterization of Responders. Diabetes care 46 (3) (2023)
Mark R Rigby, Beverly Hayes, Yinglei Li, Frank Vercruysse, Joseph A Hedrick, Teresa Quattrin
Two-Year Follow-up From the T1GER Study: Continued Off-Therapy Metabolic Improvements in Children and Young Adults With New-Onset T1D Treated With Golimumab and Characterization of Responders. Diabetes care (2022)